These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 38967906)

  • 21. Alcohol Use Disorder: The Role of Medication in Recovery.
    Mason BJ; Heyser CJ
    Alcohol Res; 2021; 41(1):07. PubMed ID: 34113531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study.
    Wallach JD; Gueorguieva R; Phan H; Witkiewitz K; Wu R; O'Malley SS
    Alcohol Clin Exp Res; 2022 Jul; 46(7):1331-1339. PubMed ID: 35616436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
    Krishnan-Sarin S; O'Malley S; Krystal JH
    Alcohol Res Health; 2008; 31(4):400-7. PubMed ID: 23584013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
    Castrén S; Mäkelä N; Alho H
    Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
    Buri C; Moggi F; Giovanoli A; Strik W
    Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
    McPheeters M; O'Connor EA; Riley S; Kennedy SM; Voisin C; Kuznacic K; Coffey CP; Edlund MD; Bobashev G; Jonas DE
    JAMA; 2023 Nov; 330(17):1653-1665. PubMed ID: 37934220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
    Votaw VR; Mann K; Kranzler HR; Roos CR; Nakovics H; Witkiewitz K
    Drug Alcohol Depend; 2022 Mar; 232():109257. PubMed ID: 35042096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baclofen for alcohol use disorder.
    Minozzi S; Saulle R; Rösner S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of healthcare utilization among patients treated with alcoholism medications.
    Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
    Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
    Liang J; Olsen RW
    Acta Pharmacol Sin; 2014 Aug; 35(8):981-93. PubMed ID: 25066321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Petrov I; Krogh J; Nordentoft M
    Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?
    Antonelli M; Sestito L; Tarli C; Addolorato G
    Eur J Intern Med; 2022 Sep; 103():13-22. PubMed ID: 35597734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quadruple pharmacotherapy for alcohol use disorder tolerable yet insufficient: a case report.
    Terasaki D; Ellinwood A; White D
    Subst Abuse Treat Prev Policy; 2024 Feb; 19(1):18. PubMed ID: 38424567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
    Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baclofen for alcohol use disorder.
    Agabio R; Saulle R; Rösner S; Minozzi S
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in the adoption of medications for alcohol dependence.
    Ducharme LJ; Knudsen HK; Roman PM
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S13-9. PubMed ID: 17114950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel human laboratory model for screening medications for alcohol use disorder.
    Ho D; Towns B; Grodin EN; Ray LA
    Trials; 2020 Nov; 21(1):947. PubMed ID: 33225963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The state of pharmacotherapy for the treatment of alcohol dependence.
    Garbutt JC
    J Subst Abuse Treat; 2009 Jan; 36(1):S15-23; quiz S24-5. PubMed ID: 19062347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The pharmacologic treatment of the alcohol dependence].
    Castro LA; Baltieri DA
    Braz J Psychiatry; 2004 May; 26 Suppl 1():S43-6. PubMed ID: 15729444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.